SLC6A1: Sodium- and chloride-dependent GABA transporter 1
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Mediates transport of gamma-aminobutyric acid (GABA) together with sodium and chloride and is responsible for the reuptake of GABA from the synapse.
- Drugs that act on it: 1
- Approved: 1
- In phases 1 to 3: 0
- Sponsors: 1
Who Is On It, and How Far Along
Every drug ChEMBL records acting on SLC6A1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule
The Landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.| Drug | Furthest stage | Sponsor | Modality | Action | Mechanism | Open trials | Warnings |
|---|---|---|---|---|---|---|---|
| Tiagabine | Approved | Teva Pharmaceutical Industries | Small molecule | Inhibitor | GABA transporter 1 inhibitor | 1 | — |
Open Trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 1 in all, from ClinicalTrials.gov.| Trial | Drug | Phase | Status | Lead sponsor | First posted |
|---|---|---|---|---|---|
| Treating Schizophrenia by Correcting Abnormal Brain Development | Tiagabine | Phase 3 | Active, not recruiting | Beth Israel Deaconess Medical Center | 2005-09-16 |
Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Epilepsy with myoclonic atonic seizures
- 0.76
- Seizure
- 0.59
- Hereditary disease
- 0.55
- Intellectual disability
- 0.50
- Epilepsy
- 0.48
- Neurodevelopmental delay
- 0.48
- Neurodevelopmental disorder
- 0.43
- Refractive error
- 0.40
- Generalized anxiety disorder
- 0.38
- Autosomal dominant non-syndromic intellectual disability
- 0.37
- Smoking initiation
- 0.35
- Abnormality of refraction
- 0.34
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1903, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P30531, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets